Sex hormones and their impact on dementia and depression: a clinical perspective

Bibliography

• UNITED NATIONS: World Population Prospects 1988.Publication No. 106. Department of Economic and Social Affairs, New York, USA, (1998).
   Google Scholar
• VAN DER WEYDEN M: The burden of disease and injuryin Australia: time for action. Med. J Aust. (1999) 171:581–582.
   PubMedGoogle Scholar
• HENDERSON AS, JORM AF: Dementia in Australia. Agedand Community Care Service Development and Evaluation Reports, Canberra, Australia (1998).
   Google Scholar
• HENDERSON AS, JORM AF, MACKINNON A et al: Theprevalence of depressive disorders and the distribu-tion of depressive symptoms in later life: a survey using Draft ICD-10 and DSM-III-R. Psycho]. Med. (1993) 23:719–729.
   PubMed Web of Science ®Google Scholar
• JOHNSON J, WEISSMAN MM, KLERMAN GL: Serviceutilization and social morbidity associated with depressive symptoms in the community. JAMA (1992) 267:1478–1483
   PubMed Web of Science ®Google Scholar
• HENDERSON AS, KORTEN AE, JACOMB PA et al: Thecourse of depression in the elderly: a longitudinal community-based study in Australia. Psycho]. Med. (1997) 27:119–129.
   PubMed Web of Science ®Google Scholar
• YAFFE K, SAWAYA G, LIEBERBURG I, GRADY D: Estrogentherapy in postmenopausal women: effects on cognitive function and dementia. JAMA (1998) 279:688–695.
   PubMed Web of Science ®Google Scholar
• MCEWEN BS, ALVES SE, BULLOCH K, WEILAND NG:Clinically relevant basic science studies of gender differences and sex hormone effects. Psychopharmacol Bull. (1998) 34:251–259.
   PubMed Web of Science ®Google Scholar
• PETANCESKA SS, NAGY V, FRAIL D, GANDY S: Ovariec-tomy and 1 713-estradiol modulate the levels of Alzheimer's amyloid 13 peptides in brain. Neurology (2000) 54:2212–2217.
   PubMed Web of Science ®Google Scholar
• EBERLING JL, REED BR, COLEMAN JE, JAGUST WJ: Effectof estrogen on cerebral glucose metabolism in postmenopausal women. Neurology (2000) 55:875–877.
   PubMed Web of Science ®Google Scholar
• YAFFE K, LUI LY, GRADY D, CAULEY J, KRAMER J,CUMMINGS SR: Cognitive decline in women in relation to non-protein-bound oestradiol concentrations. Lancet (2000) 356:708–712.
   PubMed Web of Science ®Google Scholar
• •Previous similar studies have mostly measured serum concentrations of total oestradiol and have found little relationship with cognitive performance. This study reported that women with higher non-protein bound and bioavailable oestradiol were less likely to have developed cognitive impairment at 6 years follow-up (n = 425).
   Google Scholar
• YAFFE K, HAAN M, BYERS A, TANGEN C, KULLER L: Estrogen use, APOE and cognitive decline: evidence of gene-environment interaction. Neurology (2000) 54:1949–1954.
   PubMed Web of Science ®Google Scholar
• •This paper demonstrated an important gene interaction in a large sample of women (n = 2586). Among APOE-E4 negative women, current oestrogen use reduced the risk of cognitive impairment compared with never-users by almost half. There was no change in the risk of cognitive impair-ment amongst APOE-E4 carriers.
   Google Scholar
• MANLY JJ, MERCHANT CA, JACOBS DM et al.: Endoge-nous estrogen levels and Alzheimer's disease among postmenopausal women. Neurology (2000) 54:833–837.
   PubMed Web of Science ®Google Scholar
• TANG MX, JACOBS D, STERN Y et al.: Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet (1996) 348:429–432.
   PubMed Web of Science ®Google Scholar
• ••This paper was the first prospective study to report a signifi-cant reduction in the risk of AD amongst 1124 women who had used ERT.
   Google Scholar
• KAWAS C, ROSNICK S, MORRISON A et al.: A prospectivestudy of estrogen replacement therapy and the risk of developing Alzheimer's disease in the Baltimore longitudinal study of aging. Neurology (1997) 48:1517–1521.
   PubMed Web of Science ®Google Scholar
• BALDERESCHI M, DI CARLO A, LEPORE V et al.: Estrogen-replacement therapy and Alzheimer's disease in the Italian Longitudinal Study on Aging. Neurology (1998) 50:996–1002.
   PubMed Web of Science ®Google Scholar
• WARING SC, ROCCA WA, PETERSEN RC, O'BRIEN PC, TANGALOS EG, KOKMEN E: Postmenopausal estrogen replacement therapy and risk of AD: a population-based study. Neurology (1999) 52:965–970.
   PubMed Web of Science ®Google Scholar
• HENDERSON VW, PAGANINI-HILL A, MILLER BL et al.: Estrogen for Alzheimer's disease in women: random-ized, double-blind, placebo-controlled trial. Neurology (2000) 54:295–301.
   PubMed Web of Science ®Google Scholar
• MULNARD RA, COTMAN CW, KAWAS C et al.: Estrogen replacement therapy for treatment of mild to moderate Alzheimer's disease. JAMA (2000) 283:1007–1015.
   PubMed Web of Science ®Google Scholar
• ••This is currently the largest placebo-controlled study of ERTfor the treatment of patients with AD showing patients with AD do not benefit from oestrogen treatment.
   Google Scholar
• WANG PN, LIAO SQ, LIU RS eta].: Effects of estrogen on cognition, mood and cerebral blood flow in AD: a controlled study. Neurology (2000) 54:2061–2066.
   Google Scholar
• MICHAEL RP, REES HD, BONSALL RW: Sites in the male primate brain at which testosterone acts as androgen. Brain Res. (1989) 502:11–20.
   PubMed Web of Science ®Google Scholar
• SIMERLY RB, CHANG C, MURAMATSU M, SWANSON LW:Distribution of androgen and estrogen receptor mRNA-containing cells in rat brain: an in situ hybridi-zation study. J. Comp. Neurol. (1990) 294:76–95.
   PubMed Web of Science ®Google Scholar
• DAY JR, FRANK AT, O'CALLAGHAN JP, JONES BC, ANDERSON JE: The effect of age and testosterone on the expression of glial fibrillary acidic protein in the rat cerebellum. Exp. Neurol. (1998) 151:343–346.
   PubMed Web of Science ®Google Scholar
• PAPASOZOMENOS SC: The heat shock-induced hyperphsophorylation of tau is estrogen-independent and prevented by androgen: implications for Alzheimer's disease. Proc. Natl. Acad. Sci. USA (1997) 94:6612–6617.
   PubMed Web of Science ®Google Scholar
• •This paper presents interesting evidence suggesting an interaction between sex hormones and the pathogenic process of AD in an animal (rat) model.
   Google Scholar
• GOURAS GK, XU H, GROSS RS et al.: Testosterone reduces neuronal secretion of Alzheimer's 13-amyloid peptides. Proc. Natl. Acad. Sci. USA (2000) 97:1202–1205.
   PubMed Web of Science ®Google Scholar
• •This study used neuronal cultures from the brains of rats (N2a cells and primary cerebrocortical neurones) to demonstrate that testosterone reduces the levels of P-amyloid secreted by brain cells.
   Google Scholar
• JANOWSKY JS, OVIATT SK, ORWOLL ES: Testosterone influences spatial cognition in older men. Behav. Neurosci. (1994) 108:325–332.
   PubMed Web of Science ®Google Scholar
• MOFFAT SD, HAMPSON E: A curvilinear relationship between testosterone and spatial cognition in humans: possible influences of hand preference. Psychoendocrinology (1996) 21:323–337.
   PubMed Web of Science ®Google Scholar
• VAN GOOZEN SHM, COHEN-KETTENIS PT, GOOREN LJG et al: Activating effects of androgens on cognitive performance: causal evidence in a group of female-to-male transsexuals. Neuropsychologia (1994) 32:1153–1157.
   PubMedGoogle Scholar
• •This paper shows the development of a traditionally 'male' cognitive pattern in female-to-male transsexuals, following 3 months of testosterone administration.
   Google Scholar
• ALMEIDA OP, RIONO A, CLARNETTE R, MARTINS RN: Decreased plasma testosterone levels in Alzheimer's disease and aged controls from Australia. Alzheimer's Reports (2000) 3:15–18.
   Google Scholar
• TWIST SJ, TAU PR GA, WEDDELL A, WEIGHTMAN DR,EDWARDSON JA, MORRIS CM: Brain oestradiol and testosterone levels in Alzheimer's disease. Neurosci. Lett. (2000) 286:1–4.
   PubMedGoogle Scholar
• PARKER LN, LEVIN ER, LIFRAK ET: Evidence of adreno-cortical adaptation to severe illness. J. Clin. Endocrinol. Metab. (1985) 60:947–952.
   PubMed Web of Science ®Google Scholar
• HUPPERT FA, VAN NIEKERK JK, HERBERT J: Dehydroepi-androsterone (DHEA) supplementation for cognition and well-being (Cochrane Review). In: Cochrane Library (Issue 1). Update Software, Oxford (2001).
   Google Scholar
• HALBREICH U: Role of estrogen in postmenopausal depression. Neurology (1997) 48 (Suppl. 7):16–19.
   Google Scholar
• CASPER RF, HEARN MT: The effect of hysterectomy andbilateral oophorectomy in women with severe premenstrual syndrome. Am. J. Obstet. Gynecol. (1990) 162:105–109.
   PubMed Web of Science ®Google Scholar
• ANGOLD A, COSTELLO EJ, ERKANLI A, WORTHMAN CM:Pubertal changes in hormone levels and depression in girls. Psycho]. Med. (1999) 29:1043–1053.
   PubMed Web of Science ®Google Scholar
• WATSON NR, STUDD JWW, SAVVAS M, BABER RJ: Thelong-term effects of estradiol implant therapy for the treatment of premenstural syndrome. Gynecol Endocrinol. (1990) 4:99–107
   PubMedGoogle Scholar
• SCHMIDT PJ, NIEMAN LK, DANACEAU MA, ADAMS LF,RUBINOW DR: Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. N. Engl. J. Med. (1998) 338:209–216.
   PubMed Web of Science ®Google Scholar
• •This paper demonstrated that 10/20 women with premen-strual dysphoria improved following administration of a gonadotropin-releasing hormone agonist. When hormones were re-introduced, symptoms were again present.
   Google Scholar
• SICHEL DA, COHEN LS, ROBERTSON LM, RUTTEMBERG A,ROSENBAUM JF: Prophylactic estrogen in recurrent postpartum affective disorder. Biol. Psychiatry (1995) 38:814–818.
   PubMed Web of Science ®Google Scholar
• BLOCH M, SCHMIDT PJ, DANACEAU M, MURPHY J, NIEMAN L, RUBINOW DR: Effects of gonadal steroids in women with a history of postpartum depression. Am. Psychiatry (2000) 157:924–930.
   PubMed Web of Science ®Google Scholar
• •This interesting study was designed to mimic the hormonal environment of pregnancy in women with and without a history of postpartum depression. The authors were able to demonstrate that most of the women with a history of postpartum depression and none of the controls developed depressive symptoms.
   Google Scholar
• LAWRIE TA, HOFMEYER GJ, DE JAGER M, BERK M, PAIKER J, VILJOEN E: A double-blind randomised placebo-controlled trial of postnatal norethisterone enanthate: the effect on postnatal depression and serum hormones. Br.J. Obstet. Gynaecol (2000) 105:1082–1090.
   Google Scholar
• •This paper reports the effects of a random assignment of 180 women to a single im. injection progestogen (200 mg) or placebo within 48 h of giving birth. It was demonstrated that those receiving progestogen were significantly more likely to report depressive symptoms.
   Google Scholar
• GREGOIRE AJP, KUMAR R, EVERITT B, HENDERSON AF, STUDD JWW: Transdermal oestrogen for treatment of severe postnatal depression. Lancet (1996) 3 47:930–933.
   Google Scholar
• ••This trial demonstrated a superior antidepressant effect ofoestrogen replacement compared to placebo in women who became depressed following childbirth.
   Google Scholar
• NOVAES C, ALMEIDA OP, MELO NR: Mental health among perimenopausal women attending a menopause clinic: possible association with premen-strual syndrome? Climacteric (1998) 1:264–270.
   PubMedGoogle Scholar
• COOPE J: Is oestrogen therapy effective in thetreatment of menopausal depression? J R. Gen. Pract (1981) 31:134–140.
   Google Scholar
• CAMPBELL S, WHITEHEAD M: Oestrogen therapy andthe menopause syndrome. Clin. Obstet. Gynaecol. (1977) 4 :31–47.
   PubMed Web of Science ®Google Scholar
• PEARCE J, HAWTON K, BLAKE F et al: Psychological effects of continuation versus discontinuation of hormone replacement therapy by estrogen implants: a placebo-controlled study. J Psychosom. Res. (1997) 42:177–186.
   PubMedGoogle Scholar
• SCHMIDT PJ, NIEMAN L, DANACEAU MA et al: Estrogen replacement in perimenopause-related depression: a preliminary report. Am. J. Obstet. Gynecol. (2000) 183:414–420.
   PubMed Web of Science ®Google Scholar
• •Most studies of the relationship between oestrogen and mood after the menopause use random community samples of volunteers, which may not have a high prevalence of depression. At the time of writing, this study was the only available clinical trial of the effects of oestrogen replacement in perimenopausal women with clinical depression.
   Google Scholar
• SOARES CN, ALMEIDA OP, JOFFE H, COHEN LS: Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women. Arch Gen. Psychiatry (In Press).
   Google Scholar
• GONZALES MI, FARABOLLINI F, ALBONETTI E, WILSON CA: Interaction between 5-hydroxytryptamine (5-111) and testosterone in the control of sexual and nonsexual behaviour in male and female rats. Pharmacol Biochem. Behav. (1994) 47:591–601.
   PubMedGoogle Scholar
• GRAY A, BERLIN JA, MCKINLAY JB, LONGCOPE C: An examination of research design effects on the associa-tion of testosterone and male aging: results of a meta-analysis. J Gun. Epidemiol (1991) 7:671–684.
   Google Scholar
• DABS JM, HARGROVE MF, JURKOVIC GJ: Testosterone differences among college fraternities: well-behaved vs. rambunctious. Personal. Individ. Diff. (1996) 20:157–161.
   Google Scholar
• POPE JR HG, KOURI EM, HUDSON JI: Effects ofsupraphysiologic doses of testosterone on mood and aggression in normal men: a randomized controlled trial. Arch. Gen. Psychiatry (2000) 57 :133–140.
   PubMedGoogle Scholar
• MAZUR A: Biosocial models of deviant behavior among male army veterans. Biol. Psychol (1995) 41:271–293.
   PubMed Web of Science ®Google Scholar
• BOOTH A, JOHNSON DR, GRANGER DA: Testosterone and men's depression: the role of social behavior. J Health Soc. Behav. (1999) 40:130–140.
   PubMed Web of Science ®Google Scholar
• •This study of a large sample of 4393 men showed an inverse relationship between testosterone levels and depression scores.
   Google Scholar
• SCHWEIGER U, DEUSCHELE M, WEBER B et al.: Testos- terone, gonadotropin and cortisol secretion in male patients with major depression. Psychosom. Med. (1999) 61:292–296.
   PubMed Web of Science ®Google Scholar
• SEIDMAN SN, RABKIN JG: Testosterone replacement therapy for hypogonadal men with SSRI-refractory depression. J. Affect. Disord. (1998) 48:157–161.
   PubMed Web of Science ®Google Scholar
• RABKIN JG, WAGNER GJ, RABKIN R: A double-blind, placebo-controlled trial of testosterone therapy for H1V-positive men with hypogonadal symptoms. Arch. Gen. Psychiatry (2000) 57:141–147.
   PubMed Web of Science ®Google Scholar
• •This short, placebo-controlled study was able to demonstrate a significant reduction of depressive scores amongst HIV infected men following the administration of testosterone.
   Google Scholar
• HEUSER I, DEUSCHLE M, LUPPA P, SCHWEIGER U, STANDHARDT H, WEBER B: Increased diurnal plasma concentrations of dehydroepiandrosterone in depressed patients. J. Clin. Endocrinol Metab. (1998) 83:3130–3133.
   PubMed Web of Science ®Google Scholar
• BARRETT-CONNOR E, VON MÜHLEN D, LAUGHLIN GA,KRIPKE A: Endogenous levels of dehydroepiandros-terone sulfate but not other sex hormones, are associ-ated with depressed mood in older women: the Rancho Bernardo study. J. Am. Geriatr. Soc. (1999) 47:685–691.
   PubMed Web of Science ®Google Scholar
• BARNHART KT, FREEMAN E, GRISSO JA et al.: The effectof deydroepiandrosterone supplementation to symptomatic perimenopausal women on serum endocrine profiles, lipid parameters and health-related quality of life. J. Clin. Endocrinol. Metab. (1999) 84:3896–3902.
   PubMed Web of Science ®Google Scholar
• BLOCH M, SCHMIDT PJ, DANACEAU M, ADAMS LF, RUBINOW DR: Dehydroepiandrosterone treatment of midlife dysthymia. Biol. Psychiatry (1999) 45:1533–1541.
   PubMed Web of Science ®Google Scholar
• WOLKOWITZ OM, REUS VI, KEEBLER A et al.: Double-blind treatment of major depression with dehydroepi-androsterone. Am. J Psychiatry (1999) 156:646–649.
   PubMed Web of Science ®Google Scholar